Medicare Secures 71% Discount on Novo Nordisk’s Ozempic and Wegovy
Washington, D.C., November 25, 2025 — In a significant development for Medicare beneficiaries, the U.S. government announced on Tuesday that it has negotiated a substantial 71% discount on the list prices of Novo Nordisk A/S’s widely used injectable drugs, Ozempic and Wegovy. These medications, known for their effectiveness in managing type 2 diabetes and obesity respectively, will become considerably more affordable for millions of seniors enrolled in the federal health insurance program.
Landmark Pricing Agreement Under New Legislation
Historically, Medicare has benefited from substantial rebates and discounts on prescription drugs; however, the exact terms of these agreements have rarely been publicly disclosed. This newly revealed pricing is a direct result of a Biden administration-era law aimed at enhancing drug price transparency and reducing the financial burden on patients. The agreed-upon discount will take effect in 2027, marking a new chapter in government negotiations with pharmaceutical manufacturers.
Rachel Cohrs Zhang, Madison Muller, and John Tozzi from Bloomberg, who reported the announcement, highlighted the importance of this move as part of broader efforts to address soaring prescription drug costs in the United States.
Broader Impacts on High-Cost Medications
In addition to the savings on Ozempic and Wegovy, the Centers for Medicare and Medicaid Services (CMS) disclosed that Pfizer Inc.’s breast cancer drug Ibrance will experience a 50% price reduction compared to its 2024 list price. These price cuts demonstrate the government’s expanding initiative to leverage Medicare’s purchasing power to make essential, high-cost medications more accessible.
What This Means for Patients
Ozempic and Wegovy have gained significant attention for their roles in diabetes management and weight loss treatment. The availability of these drugs at a reduced cost through Medicare is expected to improve medication adherence and health outcomes among seniors who require them.
Medicare officials emphasize that while the discounts are substantial, the program will continue to work towards making a wider range of critical medications affordable and accessible to all eligible Americans.
Looking Ahead
The new pricing agreements are set to take effect in 2027, providing the government and beneficiaries with time to prepare for the changes. Stakeholders in the healthcare and pharmaceutical industries will be watching closely to see how these negotiations shape future drug pricing and policy decisions.
For Medicare enrollees, this announcement brings promising news of relief from the high costs of some of the most important medications used to manage chronic and life-threatening conditions.
For additional information and updates on Medicare drug pricing, readers can refer to the Centers for Medicare and Medicaid Services and official government releases.